Mirabegron has been registered as the first strong and selective agonist of the β3 receptor. It is currently used for relief of symptoms of overactive bladder (OAB). That onerous illness involving urgency and detrusor overactivity, that may be accompanied by incontinence, affects approx. 16% of the population. Before registration of Mirabegron, the main pharmacological and non-surgical therapeutic method was the treatment with anti-muscarinic drugs, associated with burdensome adverse effects. Clinical trials on over 10,000 participants demonstrated efficacy and safety of Mirabegron. Besides monotherapy, attempts are being made to use Mirabegron in combined therapy of OAB. The innovative mechanism of action of the drug makes it an attractive option not only in treatment of conditions of the urinary system, but also of metabolic disorders and diseases of the cardiovascular system. This article provides a review of the current knowledge and recent reports regarding Mirabegron - an alternative in treatment of the common and onerous disease of overactive bladder.

mirabegron; overactive bladder; review

European Medicines Agency. Betmiga: Product Information. 2013 Jan 15 [updated 2017 Nov 15, cited 2018 Jun 18]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002388/WC500137309.pdf

Wagg A, Diles D, Berner T. Treatment patterns for patients on overactive bladder therapy: A retrospective statistical analysis using Canadian claims data. JHEOR 2015;3:43-55.

Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004; 64: 2–6.

Cypess, A. M., Weiner, L. S., Roberts-Toler, C., Elía, E. F., Kessler, S. H., Kahn, P. A., ... & Kolodny, G. M. (2015). Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell metabolism, 21(1), 33-38.

Bundgaard, H., Axelsson, A., Hartvig Thomsen, J., Sørgaard, M., Kofoed, K. F., Hasselbalch, R., ... & Køber, L. (2017). The first‐in‐man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT‐HF trial. European journal of heart failure, 19(4), 566-575.

Herschorn, S., Chapple, C. R., Abrams, P., Arlandis, S., Mitcheson, D., Lee, K. S., ... & Robinson, D. (2017). Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU international, 120(4), 562-575.

Abrams, P., Kelleher, C., Staskin, D., Rechberger, T., Kay, R., Martina, R., ... & Ridder, A. (2015). Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). European urology, 67(3), 577-588.

Adrian Wagg (2018): Choosing oral drug therapy for overactive bladder in older people, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2018.1502270

Karl-Erik Andersson, et al.The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy. Therapeutic Advances in Urolog. 2018.

White N, Iglesia CB. Overactive bladder. Elserviel. 2016

Gormley EA et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment. Elserviel. 2015.

Robinson D et al. A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opinion on Drug Safty. 2015.

Aditya S, Mathur SK. Mirabegron: A first-in-class beta-3 agonist for overactive bladder. J Mahatma Gandhi InstMedSci 2015;20:128-33

Krauwinkel W et al. The effect of mirabegron, a potent and selective b3 -adrenoceptoragonist, on the pharmacokinetics of CYP2D6 substratesdesipramine and metoprolol. European Journal of Drug Metabolism and Pharmacokinetics. 2014.

Dehvari, N., da Silva Junior, E. D., Bengtsson, T., & Hutchinson, D. S. (2017). Mirabegron: potential off target effects and uses beyond the bladder. British journal of pharmacology.

Yoshimura, N., & Chancellor, M. B. (2003). Neurophysiology of lower urinary tract function and dysfunction. Reviews in urology, 5(Suppl 8), S3.

Alexandre, E. C., Kiguti, L. R., Calmasini, F. B., Silva, F. H., da Silva, K. P., Ferreira, R., ... & Antunes, E. (2016). Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3‐adrenoceptor activation and α1‐adrenoceptor blockade. British journal of pharmacology, 173(3), 415-428.

Chapple, C. R., Nitti, V. W., Khullar, V., Wyndaele, J. J., Herschorn, S., van Kerrebroeck, P., ... & Siddiqui, E. (2014). Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World journal of urology, 32(6), 1565-1572.

Chapple CR, Kaplan SA, Mitcheson D et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur. Urol. 2013; 63: 296–305.

Chapple CR, Amarenco G, López Aramburu MA, Everaert K, Liehne J, Lucas M, Vik V, Ridder A, Snijder R, Yamaguchi O; BLOSSOM Investigator Group. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013 Nov;32(8):1116-22. doi: 10.1002/nau.22373. Epub 2013 Feb 19

Chapple CR, Dvorak V, Radziszewski P et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int. Urogynecol. J. 2013; 24: 1447–58.

Kuo HC, Lee KS, Na Y et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol. Urodyn. 2015; 34: 685–92.

Kelleher, C., Hakimi, Z., Zur, R., Siddiqui, E., Maman, K., Aballéa, S., ... & Chapple, C. (2018). Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. European Urology.

Khullar, V., Amarenco, G., Angulo, J. C., Blauwet, M. B., Nazir, J., Odeyemi, I. A., & Hakimi, Z. (2016). Patient‐reported outcomes with the β3‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and urodynamics, 35(8), 987-994.

Warren, K., Burden, H., & Abrams, P. (2016). Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Therapeutic advances in drug safety, 7(5), 204-216.

Rosa, G. M., Ferrero, S., Nitti, V. W., Wagg, A., Saleem, T., & Chapple, C. R. (2016). Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. European urology, 69(2), 311-323.

Sebastianelli, A., Russo, G. I., Kaplan, S. A., McVary, K. T., Moncada, I., Gravas, S., ... & Gacci, M. (2018). Systematic review and meta‐analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. International Journal of Urology, 25(3), 196-205.

Yamaguchi, O., Marui, E., Igawa, Y., Takeda, M., Nishizawa, O., Ikeda, Y., & Ohkawa, S. (2015). Efficacy and Safety of the Selective β3‐Adrenoceptor Agonist Mirabegron in J apanese Patients with Overactive Bladder: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Finding Study. LUTS: Lower Urinary Tract Symptoms, 7(2), 84-92.

Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J. Urol. 2013; 189: 1388–95.

Herschorn S, Barkin J, Castro-Diaz D et al. A phase III, randomized, doubleblind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) drenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013; 82: 313–20.

Yamaguchi O, Marui E, Kakizaki H et al. Phase III, randomised, doubleblind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014; 113: 951–60.

Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol. 2013; 63: 283–95.

Batista, J. E., Kölbl, H., Herschorn, S., Rechberger, T., Cambronero, J., Halaska, M., ... & BEYOND study group. (2015). The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Therapeutic advances in urology, 7(4), 167-179.

Nitti, V. W., Rosenberg, S., Mitcheson, D. H., He, W., Fakhoury, A., & Martin, N. E. (2013). Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. The Journal of urology, 190(4), 1320-1327.

Wöllner, J., & Pannek, J. (2016). Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal cord, 54(1), 78.

Kinjo, M., Sekiguchi, Y., Yoshimura, Y., & Nutahara, K. (2018). Long‐term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial. LUTS: Lower Urinary Tract Symptoms, 10(2), 148-152.

Vouri, S. M., Kebodeaux, C. D., Stranges, P. M., & Teshome, B. F. (2017). Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Archives of gerontology and geriatrics, 69, 77-96.